Eltrombopag for treatment of thrombocytopenia-associated disorders

Bibliography

• Kelemen E, Cserhati I, Tanos B. Demonstration and some properties of human thrombopoietin in thrombocythaemic sera. Acta Haematol 1958;20(6):350-5
   PubMedGoogle Scholar
• Bartley TD, Bogenberger J, Hunt P, et al. Identification and cloning of a megakaryocyte growth and development factor that is a ligand for the cytokine receptor Mpl. Cell 1994;77(7):1117-24
   PubMed Web of Science ®Google Scholar
• de Sauvage FJ, Hass PE, Spencer SD, et al. Stimulation of megakaryocytopoiesis and thrombopoiesis by the c-Mpl ligand. Nature 1994;369(6481):533-8
   PubMed Web of Science ®Google Scholar
• Kuter DJ, Beeler DL, Rosenberg RD. The purification of megapoietin: a physiological regulator of megakaryocyte growth and platelet production. Proc Natl Acad Sci USA 1994;91(23):11104-8
   PubMed Web of Science ®Google Scholar
• Lok S, Kaushansky K, Holly RD, et al. Cloning and expression of murine thrombopoietin cDNA and stimulation of platelet production in vivo. Nature 1994;369(6481):565-8
   PubMed Web of Science ®Google Scholar
• Foster DC, Sprecher CA, Grant FJ, et al. Human thrombopoietin: gene structure, cDNA sequence, expression, and chromosomal localization. Proc Natl Acad Sci USA 1994;91(26):13023-7
   PubMed Web of Science ®Google Scholar
• Gurney AL, Kuang WJ, Xie MH, et al. Genomic structure, chromosomal localization, and conserved alternative splice forms of thrombopoietin. Blood 1995;85(4):981-8
   PubMed Web of Science ®Google Scholar
• Hokom MM, Lacey D, Kinstler OB, et al. Pegylated megakaryocyte growth and development factor abrogates the lethal thrombocytopenia associated with carboplatin and irradiation in mice. Blood 1995;86(12):4486-92
   PubMed Web of Science ®Google Scholar
• Wendling F, Vigon I, Souyri M, et al. Myeloid progenitor cells transformed by the myeloproliferative leukemia virus proliferate and differentiate in vitro without the addition of growth factors. Leukemia 1989;3(7):475-80
   PubMed Web of Science ®Google Scholar
• Souyri M, Vigon I, Penciolelli JF, et al. A putative truncated cytokine receptor gene transduced by the myeloproliferative leukemia virus immortalizes hematopoietic progenitors. Cell 1990;63(6):1137-47
   PubMed Web of Science ®Google Scholar
• Vigon I, Mornon JP, Cocault L, et al. Molecular cloning and characterization of MPL, the human homolog of the v-mpl oncogene: identification of a member of the hematopoietic growth factor receptor superfamily. Proc Natl Acad Sci USA 1992;89(12):5640-4
   PubMed Web of Science ®Google Scholar
• Drachman JG, Kaushansky K. Structure and function of the cytokine receptor superfamily. Curr Opin Hematol 1995;2(1):22-8
   PubMedGoogle Scholar
• Mignotte V, Vigon I, Boucher de Crevecoeur E, et al. Structure and transcription of the human c-mpl gene (MPL). Genomics 1994;20(1):5-12
   PubMed Web of Science ®Google Scholar
• Drachman JG, Griffin JD, Kaushansky K. The c-Mpl ligand (thrombopoietin) stimulates tyrosine phosphorylation of Jak2, Shc, and c-Mpl. J Biol Chem 1995;270(10):4979-82
   PubMed Web of Science ®Google Scholar
• Hoffmann O, Rung O, Im AR, et al. Thrombopoietin contributes to neuronal damage in experimental bacterial meningitis. Infect Immun 2011;79(2):928-36
   PubMed Web of Science ®Google Scholar
• Baker JE, Su J, Hsu A, et al. Human thrombopoietin reduces myocardial infarct size, apoptosis, and stunning following ischaemia/reperfusion in rats. Cardiovasc Res 2008;77(1):44-53
   PubMed Web of Science ®Google Scholar
• Ramsfjell V, Borge OJ, Veiby OP, et al. Thrombopoietin, but not erythropoietin, directly stimulates multilineage growth of primitive murine bone marrow progenitor cells in synergy with early acting cytokines: distinct interactions with the ligands for c-kit and FLT3. Blood 1996;88(12):4481-92
   PubMed Web of Science ®Google Scholar
• Kaushansky K, Lok S, Holly RD, et al. Promotion of megakaryocyte progenitor expansion and differentiation by the c-Mpl ligand thrombopoietin. Nature 1994;369(6481):568-71
   PubMed Web of Science ®Google Scholar
• Zauli G, Vitale M, Falcieri E, et al. In vitro senescence and apoptotic cell death of human megakaryocytes. Blood 1997;90(6):2234-43
   PubMed Web of Science ®Google Scholar
• Zeigler FC, de Sauvage F, Widmer HR, et al. In vitro megakaryocytopoietic and thrombopoietic activity of c-mpl ligand (TPO) on purified murine hematopoietic stem cells. Blood 1994;84(12):4045-52
   PubMed Web of Science ®Google Scholar
• Carver-Moore K, Broxmeyer HE, Luoh SM, et al. Low levels of erythroid and myeloid progenitors in thrombopoietin-and c-mpl-deficient mice. Blood 1996;88(3):803-8
   PubMed Web of Science ®Google Scholar
• Fanucchi M, Glaspy J, Crawford J, et al. Effects of polyethylene glycol-conjugated recombinant human megakaryocyte growth and development factor on platelet counts after chemotherapy for lung cancer. N Engl J Med 1997;336(6):404-9
   PubMed Web of Science ®Google Scholar
• Kuter DJ, Begley CG. Recombinant human thrombopoietin: basic biology and evaluation of clinical studies. Blood 2002;100(10):3457-69
   PubMed Web of Science ®Google Scholar
• Vadhan-Raj S, Murray LJ, Bueso-Ramos C, et al. Stimulation of megakaryocyte and platelet production by a single dose of recombinant human thrombopoietin in patients with cancer. Ann Intern Med 1997;126(9):673-81
   PubMed Web of Science ®Google Scholar
• Li J, Yang C, Xia Y, et al. Thrombocytopenia caused by the development of antibodies to thrombopoietin. Blood 2001;98(12):3241-8
   PubMed Web of Science ®Google Scholar
• de Sauvage FJ, Carver-Moore K, Luoh SM, et al. Physiological regulation of early and late stages of megakaryocytopoiesis by thrombopoietin. J Exp Med 1996;183(2):651-6
   PubMed Web of Science ®Google Scholar
• Italiano JEJr, Lecine P, Shivdasani RA, et al. Blood platelets are assembled principally at the ends of proplatelet processes produced by differentiated megakaryocytes. J Cell Biol 1999;147(6):1299-312
   PubMed Web of Science ®Google Scholar
• Erickson-Miller CL, Delorme E, Tian SS, et al. Preclinical activity of eltrombopag (SB-497115), an oral, nonpeptide thrombopoietin receptor agonist. Stem Cells 2009;27(2):424-30
   PubMed Web of Science ®Google Scholar
• Will B, Kawahara M, Luciano JP, et al. Effect of the nonpeptide thrombopoietin receptor agonist Eltrombopag on bone marrow cells from patients with acute myeloid leukemia and myelodysplastic syndrome. Blood 2009;114(18):3899-908
   PubMed Web of Science ®Google Scholar
• Bussel JB, Cheng G, Saleh MN, et al. Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura. N Engl J Med 2007;357(22):2237-47
   PubMed Web of Science ®Google Scholar
• Jenkins JM, Williams D, Deng Y, et al. Phase 1 clinical study of eltrombopag, an oral, nonpeptide thrombopoietin receptor agonist. Blood 2007;109(11):4739-41
   PubMed Web of Science ®Google Scholar
• Polverelli N, Catani L, Sollazzo D, et al. Platelet fluctuations during thrombopoietin-receptor agonist treatment: correlation with platelet apoptosis. Ann Hematol 2015;94(2):339-41
   PubMed Web of Science ®Google Scholar
• Erhardt J, Erickson-Miller CL, Tapley P. SB. 497115-GR, a low molecular weight TPOR agonist, does not induce platelet activation or enhance agonist-induced platelet aggregation in vitro. Blood 2004;104(11):59B-B
   Web of Science ®Google Scholar
• Haselboeck J, Kaider A, Pabinger I, et al. Function of eltrombopag-induced platelets compared to platelets from control patients with immune thrombocytopenia. Thromb Haemost 2013;109(4):676-83
   PubMed Web of Science ®Google Scholar
• Gibiansky E, Zhang J, Williams D, et al. Population pharmacokinetics of eltrombopag in healthy subjects and patients with chronic idiopathic thrombocytopenic purpura. J Clin Pharmacol 2011;51(6):842-56
   PubMed Web of Science ®Google Scholar
• Williams DD, Peng B, Bailey CK, et al. Effects of food and antacids on the pharmacokinetics of eltrombopag in healthy adult subjects: two single-dose, open-label, randomized-sequence, crossover studies. Clin Ther 2009;31(4):764-76
   PubMed Web of Science ®Google Scholar
• Bauman JW, Vincent CT, Peng B, et al. Effect of hepatic or renal impairment on eltrombopag pharmacokinetics. J Clin Pharmacol 2011;51(5):739-50
   PubMed Web of Science ®Google Scholar
• Garcia-Martin E, Martinez C, Ladero JM, et al. Interethnic and intraethnic variability of CYP2C8 and CYP2C9 polymorphisms in healthy individuals. Mol Diagn Ther 2006;10(1):29-40
   PubMed Web of Science ®Google Scholar
• Neunert C, Lim W, Crowther M, et al. The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia. Blood 2011;117(16):4190-207
   PubMed Web of Science ®Google Scholar
• Rodeghiero F, Stasi R, Gernsheimer T, et al. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood 2009;113(11):2386-93
   PubMed Web of Science ®Google Scholar
• Abrahamson PE, Hall SA, Feudjo-Tepie M, et al. The incidence of idiopathic thrombocytopenic purpura among adults: a population-based study and literature review. Eur J Haematol 2009;83(2):83-9
   PubMed Web of Science ®Google Scholar
• Nurden AT, Viallard JF, Nurden P. New-generation drugs that stimulate platelet production in chronic immune thrombocytopenic purpura. Lancet 2009;373(9674):1562-9
   PubMed Web of Science ®Google Scholar
• Neunert C, Noroozi N, Norman G, et al. Severe bleeding events in adults and children with primary immune thrombocytopenia: a systematic review. J Thromb Haemost 2015;13(3):457-64
   PubMed Web of Science ®Google Scholar
• Imbach P, Barandun S, d’Apuzzo V, et al. High-dose intravenous gammaglobulin for idiopathic thrombocytopenic purpura in childhood. Lancet 1981;1(8232):1228-31
   PubMed Web of Science ®Google Scholar
• Provan D, Stasi R, Newland AC, et al. International consensus report on the investigation and management of primary immune thrombocytopenia. Blood 2010;115(2):168-86
   PubMed Web of Science ®Google Scholar
• Kaushansky K, Drachman JG. The molecular and cellular biology of thrombopoietin: the primary regulator of platelet production. Oncogene 2002;21(21):3359-67
   PubMed Web of Science ®Google Scholar
• George JN, Woolf SH, Raskob GE, et al. Idiopathic thrombocytopenic purpura: a practice guideline developed by explicit methods for the American Society of Hematology. Blood 1996;88(1):3-40
   PubMed Web of Science ®Google Scholar
• Schiffer CA. Haematological cancer: Prophylactic platelet transfusion is frequently not necessary. Nat Rev Clin Oncol 2013;10(8):431-2
   PubMed Web of Science ®Google Scholar
• George JN. For low platelets, how low is dangerous? Cleve Clin J Med 2004;71(4):277-8
   PubMed Web of Science ®Google Scholar
• Bussel JB, Provan D, Shamsi T, et al. Effect of eltrombopag on platelet counts and bleeding during treatment of chronic idiopathic thrombocytopenic purpura: a randomised, double-blind, placebo-controlled trial. Lancet 2009;373(9664):641-8
   PubMed Web of Science ®Google Scholar
• Bussel JB, Saleh MN, Vasey SY, et al. Repeated short-term use of eltrombopag in patients with chronic immune thrombocytopenia (ITP). Br J Haematol 2013;160(4):538-46
   PubMed Web of Science ®Google Scholar
• Cheng G, Saleh MN, Marcher C, et al. Eltrombopag for management of chronic immune thrombocytopenia (RAISE): a 6-month, randomised, phase 3 study. Lancet 2011;377(9763):393-402
   PubMed Web of Science ®Google Scholar
• Pabinger I, Marcher C, Khelif A, et al. Effect of Eltrombopag on platelet response, bleeding and reduction in concomitant ITP medications in adults with chronic immune thrombocytopenia (ITP) and baseline platelets < 15,000/mcl. Haematol-Hematol J 2010;95:74-5
   Web of Science ®Google Scholar
• Saleh MN, Bussel JB, Cheng G, et al. Safety and efficacy of eltrombopag for treatment of chronic immune thrombocytopenia: results of the long-term, open-label EXTEND study. Blood 2013;121(3):537-45
   PubMed Web of Science ®Google Scholar
• Gonzalez-Lopez TJ, Pascual C, Alvarez-Roman MT, et al. Successful discontinuation of eltrombopag after complete remission in patients with primary immune thrombocytopenia. Am J Hematol 2015;90(3):E40-3
   PubMed Web of Science ®Google Scholar
• Ghadaki B, Nazi I, Kelton JG, et al. Sustained remissions of immune thrombocytopenia associated with the use of thrombopoietin receptor agonists. Transfusion 2013;53(11):2807-12
   PubMed Web of Science ®Google Scholar
• Gonzalez-Porras JR, Mingot-Castellano ME, Andrade MM, et al. Use of eltrombopag after romiplostim in primary immune thrombocytopenia. Br J Haematol 2015;169(1):111-16
   PubMed Web of Science ®Google Scholar
• Cheng Y, Wong RS, Soo YO, et al. Initial treatment of immune thrombocytopenic purpura with high-dose dexamethasone. N Engl J Med 2003;349(9):831-6
   PubMed Web of Science ®Google Scholar
• Gomez-Almaguer D, Herrera-Rojas MA, Jaime-Perez JC, et al. Eltrombopag and high-dose dexamethasone as frontline treatment of newly diagnosed immune thrombocytopenia in adults. Blood 2014;123(25):3906-8
   PubMed Web of Science ®Google Scholar
• Young NS, Calado RT, Scheinberg P. Current concepts in the pathophysiology and treatment of aplastic anemia. Blood 2006;108(8):2509-19
   PubMed Web of Science ®Google Scholar
• Olnes MJ, Scheinberg P, Calvo KR, et al. Eltrombopag and improved hematopoiesis in refractory aplastic anemia. N Engl J Med 2012;367(1):11-19
   PubMed Web of Science ®Google Scholar
• Desmond R, Townsley DM, Dumitriu B, et al. Eltrombopag restores trilineage hematopoiesis in refractory severe aplastic anemia that can be sustained on discontinuation of drug. Blood 2014;123(12):1818-25
   PubMed Web of Science ®Google Scholar
• Marsh JC, Mufti GJ. Eltrombopag: a stem cell cookie? Blood 2014;123(12):1774-5
   PubMed Web of Science ®Google Scholar
• Bao W, Bussel JB, Heck S, et al. Improved regulatory T-cell activity in patients with chronic immune thrombocytopenia treated with thrombopoietic agents. Blood 2010;116(22):4639-45
   PubMed Web of Science ®Google Scholar
• Maciejewski JP, Selleri C. Evolution of clonal cytogenetic abnormalities in aplastic anemia. Leuk Lymphoma 2004;45(3):433-40
   PubMed Web of Science ®Google Scholar
• Fouad YM. Chronic hepatitis C-associated thrombocytopenia: aetiology and management. Trop Gastroenterol 2013;34(2):58-67
   PubMedGoogle Scholar
• 2011 European Association of the Study of the Liver hepatitis C virus clinical practice guidelines. Liver Int 2012;32(Suppl 1):2-8
   Web of Science ®Google Scholar
• Maan R, van der Meer AJ, Hansen BE, et al. Effect of thrombocytopenia on treatment tolerability and outcome in patients with chronic HCV infection and advanced hepatic fibrosis. J Hepatol 2014;61(3):482-91
   PubMed Web of Science ®Google Scholar
• McHutchison JG, Dusheiko G, Shiffman ML, et al. Eltrombopag for thrombocytopenia in patients with cirrhosis associated with hepatitis C. N Engl J Med 2007;357(22):2227-36
   PubMed Web of Science ®Google Scholar
• Afdhal NH, Dusheiko GM, Giannini EG, et al. Eltrombopag increases platelet numbers in thrombocytopenic patients with HCV infection and cirrhosis, allowing for effective antiviral therapy. Gastroenterology 2014;146(2):442-52; e1
   PubMed Web of Science ®Google Scholar
• Afdhal NH, Giannini EG, Tayyab G, et al. Eltrombopag before procedures in patients with cirrhosis and thrombocytopenia. N Engl J Med 2012;367(8):716-24
   PubMed Web of Science ®Google Scholar
• Kantarjian H, Giles F, List A, et al. The incidence and impact of thrombocytopenia in myelodysplastic syndromes. Cancer 2007;109(9):1705-14
   PubMed Web of Science ®Google Scholar
• Gonzalez-Porras JR, Cordoba I, Such E, et al. Prognostic impact of severe thrombocytopenia in low-risk myelodysplastic syndrome. Cancer 2011;117(24):5529-37
   PubMed Web of Science ®Google Scholar
• Mavroudi I, Pyrovolaki K, Pavlaki K, et al. Effect of the nonpeptide thrombopoietin receptor agonist eltrombopag on megakaryopoiesis of patients with lower risk myelodysplastic syndrome. Leuk Res 2011;35(3):323-8
   PubMed Web of Science ®Google Scholar
• Oliva EN, Santini V, Zini G, et al. Efficacy and Safety of Eltrombopag for the Treatment of Thrombocytopenia of Low and Intermediate-1 IPSS Risk Myelodysplastic Syndromes: Interim Analysis of a Prospective, Randomized, Single-Blind, Placebo-Controlled Trial (EQoL-MDS). Blood 2012;120:21
   PubMedGoogle Scholar
• Svensson T, Chowdhury O, Garelius H, et al. A pilot phase I dose finding safety study of the thrombopoietin-receptor agonist, eltrombopag, in patients with myelodysplastic syndrome treated with azacitidine. Eur J Haematol 2014;93(5):439-45
   PubMed Web of Science ®Google Scholar
• Platzbecker U, Wong RSM, Verma A, et al. Randomized, Placebo-Controlled, Phase I/II Trial Of The Thrombopoietin Receptor Agonist Eltrombopag In Thrombocytopenic Patients With Advanced Myelodysplastic Syndromes Or Acute Myeloid Leukemia - A Subgroup Analysis Of Patients Receiving Concomitant Anticancer Therapy. Blood 2013;122:21
   Web of Science ®Google Scholar
• Liesveld JL, Phillips GLII, Becker M, et al. A phase 1 trial of eltrombopag in patients undergoing stem cell transplantation after total body irradiation. Biol Blood Marrow Transplant 2013;19(12):1745-52
   PubMed Web of Science ®Google Scholar
• Bussel JB, De Miguel PG, Despotovic J, et al. Eltrombopag for the treatment of children with persistent and chronic immune thrombocytopenia (PETIT): a randomised, multicentre, placebo-controlled study. Lancet Haematol 2015;2(8):e315-e25
   PubMed Web of Science ®Google Scholar
• Grainger JD, Locatelli F, Chotsampancharoen T, et al. Eltrombopag for children with chronic immune thrombocytopenia (PETIT2): a randomised, multicentre, placebo-controlled trial. Lancet 2015. [Epub ahead of print]
   PubMedGoogle Scholar
• Bussel JB, Cheng G, Saleh MN, et al. Incidence of Thromboembolic Events Across Eltrombopag Clinical Trials In Chronic Immune Thrombocytopenia (ITP). Blood 2010;116(21):37-8
   Web of Science ®Google Scholar
• Boiocchi L, Orazi A, Ghanima W, et al. Thrombopoietin receptor agonist therapy in primary immune thrombocytopenia is associated with bone marrow hypercellularity and mild reticulin fibrosis but not other stromal abnormalities. Mod Pathol 2012;25(1):65-74
   PubMed Web of Science ®Google Scholar
• Ghanima W, Junker P, Hasselbalch HC, et al. Fibroproliferative activity in patients with immune thrombocytopenia (ITP) treated with thrombopoietic agents. Br J Haematol 2011;155(2):248-55
   PubMed Web of Science ®Google Scholar
• Kuter DJ, Bain B, Mufti G, et al. Bone marrow fibrosis: pathophysiology and clinical significance of increased bone marrow stromal fibres. Br J Haematol 2007;139(3):351-62
   PubMed Web of Science ®Google Scholar
• Ghanima W, Geyer JT, Lee CS, et al. Bone marrow fibrosis in 66 patients with immune thrombocytopenia treated with thrombopoietin-receptor agonists: a single-center, long-term follow-up. Haematologica 2014;99(5):937-44
   PubMed Web of Science ®Google Scholar
• Boyers D, Jia X, Jenkinson D, et al. Eltrombopag for the treatment of chronic immune or idiopathic thrombocytopenic purpura: a NICE single technology appraisal. Pharmacoeconomics 2012;30(6):483-95
   PubMed Web of Science ®Google Scholar
• Gerrits AJ, Leven EA, Frelinger ALIII, et al. Effects of eltrombopag on platelet count and platelet activation in Wiskott-Aldrich syndrome/X-linked thrombocytopenia. Blood 2015; Epub ahead of print
   Google Scholar